Literature DB >> 3746385

Response variability of human brain tumors to AZQ in tissue culture.

P L Kornblith, L Rosa, J D Bona, J A Edwards, N Matuzic, A Hirschfeld, C Hawkins.   

Abstract

In a series of 28 glioma-derived cell cultures and 6 non-gliomatous CNS tumors, AZQ has been found to have varying degrees of growth inhibiting or cytotoxic activity in nearly all lines tested at doses greater than 100 mcg/ml. At dose levels comparable to the clinically achieved levels (1 mcg/ml), AZQ was found to have a cytotoxic effect in 8 of 28 glioma-derived and 2 of 6 non-gliomatous cell lines tested. These findings suggest that AZQ has activity against certain glioma-derived cells in culture at a response ratio similar to that seen in vivo. There, appear to be significant differences in the degree of responsiveness in different patients' tumor cells which can be detected in vitro prior to clinical treatment.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3746385     DOI: 10.1007/bf02158002

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  19 in total

1.  Evaporation as a cause of positional differences in cell plating and growth in microtiter plates.

Authors:  R L Martuza; M R Proffitt; M B Moore; C F Dohan
Journal:  Transplantation       Date:  1976-03       Impact factor: 4.939

2.  The generality of methylglyoxal bis(guanylhydrazone)-induced mitochondrial damage and the dependence of this effect on cell proliferation.

Authors:  F Mikles-Robertson; B Feuerstein; C Dave; C W Porter
Journal:  Cancer Res       Date:  1979-06       Impact factor: 12.701

3.  Structure-antitumor activity relationships among quinone derivatives.

Authors:  J S Driscoll; G F Hazard; H B Wood; A Goldin
Journal:  Cancer Chemother Rep 2       Date:  1974-04

4.  Potential central nervous system antitumor agents. Aziridinylbenzoquinones. 1.

Authors:  A H Khan; J S Driscoll
Journal:  J Med Chem       Date:  1976-02       Impact factor: 7.446

5.  Mitochondrial toxicity of 2,5-diaziridinyl-3,6-bis-(carboethoxyamino)-1,4-benzoquinone.

Authors:  M A Oberc-Greenwood; B H Smith; C Cooke; J R Ellis; P L Kornblith; P E McKeever
Journal:  J Natl Cancer Inst       Date:  1983-10       Impact factor: 13.506

6.  Phase I trial and pharmacokinetics of aziridinylbenzoquinone (NSC 182986) in humans.

Authors:  R L Schilsky; J A Kelley; D C Ihde; D M Howser; R S Cordes; R C Young
Journal:  Cancer Res       Date:  1982-04       Impact factor: 12.701

7.  Phase II and pharmacokinetic study of aziridinylbenzoquinone [2,5-diaziridinyl-3,6-bis(carboethoxyamino)-1,4-benzoquinone, diaziquone, NSC 182986] in high-grade gliomas.

Authors:  G A Curt; J A Kelley; C V Kufta; B H Smith; P L Kornblith; R C Young; J M Collins
Journal:  Cancer Res       Date:  1983-12       Impact factor: 12.701

8.  Potential CNS antitumor agents VI: aziridinylbenzoquinones III.

Authors:  J S Driscoll; L Dudeck; G Congleton; R I Geran
Journal:  J Pharm Sci       Date:  1979-02       Impact factor: 3.534

9.  Biochemical activation of AZQ [3,6-diaziridinyl-2,5-bis(carboethoxyamino)-1,4-benzoquinone] to its free radical species.

Authors:  P L Gutierrez; R D Friedman; N R Bachur
Journal:  Cancer Treat Rep       Date:  1982-02

10.  Biophysical properties of human astrocytic brain tumor cells in cell culture.

Authors:  P M Black; P L Kornblith
Journal:  J Cell Physiol       Date:  1980-12       Impact factor: 6.384

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.